Chemotherapy with fudr in the management of metastatic renal cell carcinoma

P. Aveta; C. Terrone; D. Neira; C. Cracco; S. R. Rossetti

Chemotherapy with fudr in the management of metastatic renal cell carcinoma

P. Aveta
, C. Terrone
, D. Neira
, C. Cracco
, S. R. Rossetti

Research output: Contribution to journal › Article › peer-review

Abstract

Metastatic renal cell carcinoma has a poor prognosis, requiring systemic therapy, in addition to radical nephrectomy. Since August 1989, 50 patients were treated with continuous, systemic, chronobiological infusion of FUDR (floxuridine) at our Institution. We reported 11.7 % of objective responses, a long period of stable disease and low toxicity. We also compared our actuarial survival with the results obtained with recombinant IL-2 treatment.

Original language	English
Pages (from-to)	159-163
Number of pages	5
Journal	Annales d'Urologie
Volume	31
Issue number	3
Publication status	Published - 1997
Externally published	Yes

Keywords

Chemotherapy
Floxuridine
Metastases
Renal cell carcinoma

Cite this

@article{6aedfe53a4834495ac319c5e4833c48f,

title = "Chemotherapy with fudr in the management of metastatic renal cell carcinoma",

abstract = "Metastatic renal cell carcinoma has a poor prognosis, requiring systemic therapy, in addition to radical nephrectomy. Since August 1989, 50 patients were treated with continuous, systemic, chronobiological infusion of FUDR (floxuridine) at our Institution. We reported 11.7 \% of objective responses, a long period of stable disease and low toxicity. We also compared our actuarial survival with the results obtained with recombinant IL-2 treatment.",

keywords = "Chemotherapy, Floxuridine, Metastases, Renal cell carcinoma",

author = "P. Aveta and C. Terrone and D. Neira and C. Cracco and Rossetti, \{S. R.\}",

year = "1997",

language = "English",

volume = "31",

pages = "159--163",

journal = "Annales d'Urologie",

issn = "0003-4401",

publisher = "Elsevier BV",

number = "3",

}

TY - JOUR

T1 - Chemotherapy with fudr in the management of metastatic renal cell carcinoma

AU - Aveta, P.

AU - Terrone, C.

AU - Neira, D.

AU - Cracco, C.

AU - Rossetti, S. R.

PY - 1997

Y1 - 1997

N2 - Metastatic renal cell carcinoma has a poor prognosis, requiring systemic therapy, in addition to radical nephrectomy. Since August 1989, 50 patients were treated with continuous, systemic, chronobiological infusion of FUDR (floxuridine) at our Institution. We reported 11.7 % of objective responses, a long period of stable disease and low toxicity. We also compared our actuarial survival with the results obtained with recombinant IL-2 treatment.

AB - Metastatic renal cell carcinoma has a poor prognosis, requiring systemic therapy, in addition to radical nephrectomy. Since August 1989, 50 patients were treated with continuous, systemic, chronobiological infusion of FUDR (floxuridine) at our Institution. We reported 11.7 % of objective responses, a long period of stable disease and low toxicity. We also compared our actuarial survival with the results obtained with recombinant IL-2 treatment.

KW - Chemotherapy

KW - Floxuridine

KW - Metastases

KW - Renal cell carcinoma

UR - https://www.scopus.com/pages/publications/0030738696

M3 - Article

SN - 0003-4401

VL - 31

SP - 159

EP - 163

JO - Annales d'Urologie

JF - Annales d'Urologie

IS - 3

ER -

Chemotherapy with fudr in the management of metastatic renal cell carcinoma

Abstract

Keywords

Other files and links

Fingerprint

Cite this